Uncategorized
STAT+: Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more
WASHINGTON — Last year, Congress passed a bill restricting how U.S. pharmaceutical and biotechnology companies can do business with Chinese firms. Many political leaders don’t seem to be satisfied.
Already, they’re laying the groundwork for additional legislative and regulatory measures to counter the rise of Chinese biopharma companies. And federal health officials are working to make it easier for companies to operate in the U.S.
“The itch has not been entirely scratched,” said Bobby McMillin, partner at Arnold Porter.
WASHINGTON — Last year, Congress passed a bill restricting how U.S. pharmaceutical and biotechnology companies can do business with Chinese firms. Many political leaders don’t seem to be satisfied.
Already, they’re laying the groundwork for additional legislative and regulatory measures to counter the rise of Chinese biopharma companies. And federal health officials are working to make it easier for companies to operate in the U.S.
“The itch has not been entirely scratched,” said Bobby McMillin, partner at Arnold Porter.